Top 10 Cancers Causing Death in Men
Testicular Cancer Drugs Market Forecast Report 2024-2030 - Focus On Reducing Treatment Toxicity Enhances Demand For Novel Testicular Cancer Drugs
Company Logo
Global Testicular Cancer Drugs Market
Global Testicular Cancer Drugs Market
Dublin, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The "Testicular Cancer Drugs - Global Strategic Business Report" has been added to ResearchAndMarkets.Com's offering.
The global market for Testicular Cancer Drugs was estimated at US$666.5 Million in 2023, and is projected to reach US$810 Million by 2030, growing at a CAGR of 2.8% from 2023 to 2030.
The growth in the testicular cancer drugs market is driven by several factors. Technological advancements in drug development and delivery systems are expanding the range of available treatments and improving their efficacy. The rising incidence of testicular cancer, particularly among younger men, is increasing the demand for effective therapies. Enhanced awareness and early detection efforts are also contributing to market growth by identifying cases at a stage when they are most treatable.
Furthermore, substantial investments in research and development by pharmaceutical companies are accelerating the introduction of innovative drugs. Regulatory support, including expedited approvals for breakthrough therapies, is facilitating quicker access to new treatments. Additionally, the increasing adoption of personalized medicine is generating demand for drugs tailored to the specific genetic profiles of patients` tumors.
Finally, patient advocacy groups and public health initiatives are playing a crucial role in raising awareness and supporting the adoption of new therapies, thereby driving the expansion of the testicular cancer drugs market.
Key Insights:
Market Growth: Understand the significant growth trajectory of the Seminoma Drugs segment, which is expected to reach US$356.0 Million by 2030 with a CAGR of a 2.4%. The Non-Seminoma Drugs segment is also set to grow at 3.2% CAGR over the analysis period.
Regional Analysis: Gain insights into the U.S. Market, estimated at $181.6 Million in 2023, and China, forecasted to grow at an impressive 5.4% CAGR to reach $162.2 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Key Questions Answered:
How is the Global Testicular Cancer Drugs Market expected to evolve by 2030?
What are the main drivers and restraints affecting the market?
Which market segments will grow the most over the forecast period?
How will market shares for different regions and segments change by 2030?
Who are the leading players in the market, and what are their prospects?
Report Features:
Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
Company Profiles: Coverage of major players such as Astellas Pharma, Inc., BioNTech SE, Bristol-Myers Squibb Company, and more.
Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Story continues
Key Attributes:
Report Attribute
Details
No. Of Pages
269
Forecast Period
2023 - 2030
Estimated Market Value (USD) in 2023
$666.5 Million
Forecasted Market Value (USD) by 2030
$810 Million
Compound Annual Growth Rate
2.8%
Regions Covered
Global
Key Topics Covered:
MARKET OVERVIEW
FOCUS ON SELECT PLAYERS
Astellas Pharma, Inc.
BioNTech SE
Bristol-Myers Squibb Company
Context Therapeutics
CytomX Therapeutics, Inc.
INTRAGEL
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
Sanofi
MARKET TRENDS & DRIVERS
Rising Incidence of Testicular Cancer Drives Market Growth for Therapeutic Solutions
Innovative Targeted Therapies Propel Growth in Testicular Cancer Drugs Market
Advancements in Immunotherapy Expand Addressable Market Opportunity for Testicular Cancer Treatments
Genomic and Molecular Profiling Strengthen Business Case for Personalized Medicine in Testicular Cancer
Development of Novel Chemotherapeutic Agents Spurs Demand for Effective Testicular Cancer Drugs
Enhanced Early Detection Efforts Throw the Spotlight on Testicular Cancer Treatment Market
Increased Healthcare Expenditure Spurs Growth in Testicular Cancer Drugs Market
Economic Incentives for Oncological Research Propel Investment in Testicular Cancer Drug Development
Focus on Reducing Treatment Toxicity Enhances Demand for Novel Testicular Cancer Drugs
Adoption of Precision Medicine Approaches Generates Demand for Tailored Testicular Cancer Treatments
Advancements in Biologics and Biosimilars Expand Market Opportunities for Testicular Cancer Drugs
For more information about this report visit https://www.Researchandmarkets.Com/r/nhc339
About ResearchAndMarkets.ComResearchAndMarkets.Com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
CONTACT: CONTACT: ResearchAndMarkets.Com Laura Wood,Senior Press Manager press@researchandmarkets.Com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900View comments
Utidelone By BioStar Pharmaceuticals For Testicular Cancer: Likelihood Of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Utidelone overviewUtidelone is an microtubule stabilizing agent acts as an anti-neoplastic drug. It is formulated as powder for solution for intravenous route of administration. Utidelone is indicated for the treatment of recurrent or metastatic advanced breast cancer.
UTD-1 is under development for the treatment of solid tumors including head and neck cancer squamous cell carcinoma, esophageal cancer, human epidermal growth factor receptor 2 negative breast cancer (HER2- breast cancer), breast cancer brain metastasis (BCBM), human epidermal growth factor receptor 2 positive breast cancer (HER2- breast cancer), gastric cancer, pancreatic cancer, bile duct cancer (cholangiocarcinoma), ovarian cancer, non-small cell lung cancer, metastatic castration-resistant prostate cancer, breast cancer, glioblastoma multiforme, lung cancer brain metastasis, testicular Sertoli cell tumor, pancreatic adenocarcinoma, appendiceal adenocarcinoma, carcinoma of fallopian tube, adenocarcinoma of sigmoid colon and solid tumors. It is a small molecule administered intravenously, orally and in the form of nano injection. It acts as microtubule stabilizing agent. The drug candidate is an epothilone analog generated by genetic manipulation of the polyketide biosynthetic gene cluster.
It was also under development for the treatment of metastatic colorectal cancer.
BioStar Pharmaceuticals overviewBioStar Pharmaceuticals (BioStar) is a developer, manufacturer and marketer of pharmaceutical and healthcare supplement products for various diseases and conditions. The company offers products such as huangyangning tablets, hyperthyroidism capsules, danshen granule, aoxing oleanolic acid capsule, and taohuasan and tianqi dysmenorrhea capsules. Its aoxing oleanolic acid capsule is an over-the-counter medicine used for the treatment of chronic hepatitis B. BioStar's hyperthyroidism capsules are used for the patients of hyperthyroidism with the symptoms of palpitations, sweating, irritability, dry throat, rapid pulse, and others. The company sells its products across China. BioStar is headquartered in Xianyang, China.
For a complete picture of Utidelone's drug-specific PTSR and LoA scores, buy the report here.
From 
Blending expert knowledge with cutting-edge technology, GlobalData's unrivalled proprietary data will enable you to decode what's happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
Be better informed
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData's Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData's Pharmaceutical Intelligence Center.
Local Toddler Diagnosed With Rare Testicular Cancer As Family Searches For Answers
PHOENIX - A local toddler was diagnosed with rare form of testicular cancer in a crushing medical development for him and his family.
They are now searching for answers and hope as they take on this journey.
"Adam is giving me the courage to continue smiling, even if it feels hard," said Amanda Rubin, the mother of 15-month-old Adam Rubin.
Nightmare scenario becomes fearful realityIt's the reality no parent wants to live through, learning your child has cancer.
Alex and Amanda Rubin are now learning that new fearful reality.
It was about three weeks ago their journey began after a few diaper changes on their firstborn son.
"We started to notice some swelling in his groin and from a medical standpoint we weren't sure how fast a groin should grow," said Alex.
From there it got worse so they reached out to their pediatrician.
At first it was diagnosed as an infection and he was put on antibiotics.
That didn't solve the problem, so they quickly met with a urologist for an ultrasound.
Doctor says "the tumor was about 15-times larger than a testicle should be""The doctors from Phoenix Children's Hospital said there was no infection or any issues with that. They have no reason to believe that this is not a tumor on his left testicle," said Alex.
After blood work and surgery, it was confirmed the growth was a malignant form of a cancerous germ cell tumor.
Watch FOX 10 Phoenix Live:"Our doctor told us that the tumor was about 15-times larger than a testicle should be, which is very scary," said Alex.
The family now waits for further answers from an oncologist and testing. From there, they will learn what their next steps are.
Advice for other parents: trust your gutThey say leading up to this, Adam wasn't in pain and didn't show any signs of discomfort.
Their advice to other parents is to always trust your gut.
"It's better to seek advice. It's better to ask the questions. It's better to make this phone call to the doctor and just say hey what is this? Is this something that we should be concerned about?" Alex said.
The family has set up a GoFundMe page for support.
View comments
Comments
Post a Comment